今後の課題

Kıvrakらは，メーカ間でADCの値が異なると報告している[44]．本検討で用いた拡散強調像は，

複数メーカの MRI により撮像された．装置を限定した場合，同様の結果が得られるか，追加検討 が必要である．また，腫瘍の充実部を手動抽出した．再現性の高い自動抽出の開発が望まれる．

参考文献 36

参考文献

[1] John T. Hansen, Bruce M. Koeppen著; 相磯貞和, 渡辺修一 訳．ネッター解剖生理学アトラス．

東京：南江堂，2006．

[2] Rachita. Difference between glioma and glioblastoma. Webpage. 9 June 2014.

[3] http://www.differencebetween.net/science/health/difference-between-glioma-and-glioblastoma

[4] Ramírez-Rivera, José, "Sex difference in the incidence of glioblastoma multiforme" (1953). Yale Medicine Thesis Digital Library. 3049. http://elischolar.library.yale.edu/ymtdl/3049

[5] Kikuchi K, Hiratsuka Y, Kohno S, Ohue S, Miki H, Mochizuki T. Radiological features of cerebellar glioblastoma. J Neuroradiol. 2016 Jul;43(4):260-265.

[6] Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul;16(7):984-990.

[7] Salazar OM, Rubin P. The spread of glioblastoma multiforme as a determining factor in the radiation treated volume. Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):627-37.

[8] 増井憲太, 小森隆司．放射線診断専門医に必要な脳腫瘍病理．画像診断．2016：36（13）： 1235-44．

[9] Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011 Jul;115(1):3-8.

[10] Parisi S, Corsa P, Raguso A, Perrone A, Cossa S, Munafò T, Sanpaolo G, Donno E, Clemente MA, Piombino M, Parisi F, Valle G. Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. Biomed Res Int. 2015; 620643.

[11] 畠中正光，吉浦敬，塩山善之，本田浩. 画像診断の新たな展開 MRIによる治療効果や予後の

予測. 福岡医誌 2010;101(3):41-45.

[12] Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011 Jul;115(1):3-8.

参考文献 37

[13] 日本脳神経外科学会（監），日本脳腫瘍学会（編）：脳腫瘍診療ガイドライン 2016 年版．

http://www.jsn-o.com/guideline2016/index.html

[14] Stewart LA. Chemotherapy in adult high grade glioma：a systematic review and meta—analysis of individual patient data from 12 randomised trials. Lancet 2002；359（9311）：1011—8.

[15] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med.

2005 Mar 10;352(10):987-96.

[16] Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003.

[17] Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD.

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010 Feb;12(2):116-21.

[18] Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol. 2013 Mar;15(3):370-381.

[19] Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme:

ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009 Jul;252(1):182-189.

[20] Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free

参考文献 38

survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011 May;32(5):882-889.

[21] Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 Jul;108(3):491-498.

[22] Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol. 2015 Jan;121(2):331-339.

[23] Choi YS, Ahn SS, Kim DW, Chang JH, Kang SG, Kim EH, Kim SH, Rim TH, Lee SK. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma. Radiology. 2016 Oct;281(1):175-184.

[24] Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87.

[25] Hempel JM, Schittenhelm J, Bisdas S, Brendle C, Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda Vega S, Ernemann U, Klose U. In vivo assessment of tumor heterogeneity in WHO 2016 glioma grades using diffusion kurtosis imaging: Diagnostic performance and improvement of feasibility in routine clinical practice. J Neuroradiol. 2017 Sep 1. pii: S0150-9861(17)30172-4.

[26] Just N. Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer. 2014 Dec 9;111(12):2205-13.

[27] Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. 2015 May;3(7):95.

[28] Mitsuya K, Nakasu Y, Horiguchi S, Harada H, Nishimura T, Bando E, Okawa H, Furukawa Y, Hirai T, Endo M. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol. 2010 Aug;99(1):81-8.

[29] Kondo M, Yamashita K, Yoshiura T, Hiwatashi A, Shirasaka T, Arimura H, Nakamura Y. Honda, H.

参考文献 39

Histogram analysis with automated extraction of brain-tissue region from whole-brain CT images.

SpringerPlus. 2015 4, 788.

[30] 中澤秀夫．生存時間データ解析と比例ハザードモデル．日医大医会誌．2015; 11(1):29-36.

[31] 新谷歩．今日から使える医療統計学講座【Lesson12（最終回）】カプランマイヤー曲線．Webpage.

16 April 2012. http://www.igaku-shoin.co.jp/paperDetail.do?id=PA02974_05

[32] Roger J. Porter、Bruce S. Schoenberg 編集．Controlled Clinical Trials in Neurological Disease.

Massachusetts：Kluwer Academic Publishers，1990．

[33] David G. Kleinbaum, Mitchel Klein 著．Survival Analysis: A Self-Learning Text．Berlin：Springer，

1996．

[34] Gutman DA, Cooper LA, Hwang SN, Holder CA, Gao J, Aurora TD, Dunn WD Jr, Scarpace L, Mikkelsen T, Jain R, Wintermark M, Jilwan M, Raghavan P, Huang E, Clifford RJ, Mongkolwat P, Kleper V, Freymann J, Kirby J, Zinn PO, Moreno CS, Jaffe C, Colen R, Rubin DL, Saltz J, Flanders A, Brat DJ. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology. 2013 May;267(2):560-569.

[35] Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462-477.

[36] Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984 May 1;53(9):2002-2007.

[37] McConville P, Hambardzumyan D, Moody JB, Leopold WR, Kreger AR, Woolliscroft MJ, Rehemtulla A, Ross BD, Holland EC. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res. 2007 May 15;13(10):2897-2904.

[38] Schmainda KM. Diffusion-weighted MRI as a biomarker for treatment response in glioma. CNS Oncol.

参考文献 40

2012 Nov;1(2):169-180.

[39] Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature.

2013;501(7467):355-364.

[40] Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015 May;15(5):302-310.

[41] Ryu YJ, Choi SH, Park SJ, Yun TJ, Kim JH, Sohn CH. Glioma: application of whole-tumor texture analysis of diffusion-weighted imaging for the evaluation of tumor heterogeneity. PLoS One. 2014 Sep 30;9(9):e108335.

[42] Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1):98-110.

[43] 溝口昌弘. 分子病理学に基づくグリオーマ分類. 脳外ジャーナル 2015,24 (6):366-77.

[44] Kıvrak AS, Paksoy Y, Erol C, Koplay M, Özbek S, Kara F. Comparison of apparent diffusion coefficient values among different MRI platforms: a multicenter phantom study. Diagn Interv Radiol. 2013 Nov-Dec;19(6):433-437.

謝辞 41

謝辞

本研究を遂行するにあたり，懇切かつ熱心な御指導を賜りました指導教員である本学大学院生命 科学研究部内山良一准教授に心から感謝致します．

著者研究業績 42

著者研究業績

1. 原著論文［主著］

1) Kondo M, Uchiyama Y. Apparent Diffusion Coefficient Histogram Analysis for Prediction of Prognosis in Glioblastoma. J Neuroradiol. 2017 Dec 21. In press.

2) Kondo M, Nishie A, Fujita N, Morita K, Shirasaka T, Arimura H, Nakamura Y, Honda H. Impact of hybrid iterative reconstruction on unenhanced liver CT. Br J Radiol. 2017 Feb;90(1070):20150670.

3) Kondo M, Yamashita K, Yoshiura T, Hiwatash A, Shirasaka T, Arimura H, Nakamura Y, Honda H.

Histogram analysis with automated extraction of brain-tissue region from whole-brain CT images.

Springerplus. 2015 Dec 18;4:788.

2. 原著論文［共著］

1) Shimomiya Y, Nagao M, Yamasaki Y, Shirasaka T, Kondo M, Kojima T, Nishie A, Yamamura K, Honda H. Dynamic flow imaging using 320-detector row CT and motion coherence analysis in coronary aneurysms associated with Kawasaki disease. Cardiol Young. 2017 Dec 14:1-5.

2) Nagao M, Yamasaki Y, Kamitani T, Kawanami S, Kondo M, Sonoda H, Fujioka T, Honda H. Geometrical characteristics of aortic root and left ventricular dysfunction in aortic stenosis: quantification of 256-slice coronary CT angiography. Heart Vessels. 2017 May;32(5):558-565.

3) Yamashita K, Hiwatashi A, Togao O, Kondo M, Kikuchi K, Inoguchi T, Maehara J, Kyuragi Y, Honda H.

Additive value of "otosclerosis-weighted" images for the CT diagnosis of fenestral otosclerosis. Acta Radiol. 2017 Oct;58(10):1215-1221.

4) Sakai N, Yabuuchi H, Kondo M, Kojima T, Nagatomo K, Kawanami S, Kamitani T, Yonezawa M, Nagao M, Honda H. Volumetric measurement of artificial pure ground-glass nodules at low-dose CT:

Comparisons between hybrid iterative reconstruction and filtered back projection. Eur J Radiol. 2015 Dec;84(12):2654-62.

5) Sakai N, Yabuuchi H, Kondo M, Matsuo Y, Kamitani T, Nagao M, Jinnouchi M, Yonezawa M, Kojima T, Yano Y, Honda H. Low-dose CT screening using hybrid iterative reconstruction: confidence ratings of

著者研究業績 43

diagnoses of simulated lesions other than lung cancer. Br J Radiol. 2015 Sep;88(1053):20150159.

3. 国際会議における発表

1) Kondo M, Nishie A, Sakai Y, Shirasaka T, Yoshikawa H, Umezu Y. Superior image noise suppression with higher view rate in abdominal CT with model based iterative reconstruction: a phantom study. ECR 2018, Vienna, Austria, February, 2018

2) Kondo M. Impact of Hybrid Iterative Reconstruction on Unenhanced Liver CT. Cho ray annual scientific conference 2017, Ho Chi Minh, Viet Nam, April, 2017